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In the S180 tumor bearing mice model, tumor growth inhibition was observed 
after administration of a polysaccharopeptide isolated from the edible mushroom, 
Coriolus versicolor, hereinafter called polysaccharopeptide, in the drinking water for 
29 days. The present study was thus designed to investigate three aspects, namely 
anti-proliferative, anti-angiogenic and immunomodulatory effects of this 
polysaccharopeptide. 
Polysaccharopeptide did not exert any direct cytotoxic effect in both cultured 
mouse sarcoma 180 cells and mouse splenocytes, but it inhibited the growth of 
tumors. Microcorrosion casting revealed that the tumors in the control group 
contained more angiogenic features, implying that angiogenesis was more active in 
these tumors. The vascular density in the tumor sections stained 
immunohistochemically with Factor V i n antibody, which was found to be positively 
correlated with tumor weight. When the mice were treated with polysaccharopeptide, 
the vascular density and also the tumor weight was lower. In addition, the expression 
of angiogenic gene, vascular endothelial cell growth factor (VEGF), was suppressed 
subsequently inhibiting tumor angiogenesis and tumor growth. The phenotyping of 
lymphocyte subsets from tumor-bearing mice by flow cytometry did not show any 
direct effect of the polysaccharopeptide on the relative abundance of lymphocyte 
subpopuIation, CD4+/CD8+ and CD3+/CD19+. However, it up-regulated the 
expression of WN-y in polysaccharopeptide-treated splenocytes. ffN-y is a cytokine 
which can up-regulate the activity of cytotoxic T cells, natural killer cells and 
macrophages against tumor cells and also suppress VEGF expression. In conclusion, 
the polysaccharopeptide should mediate its anti-tumor activity through anti-
angiogenesis and activation ofimmune cells. 
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Chapter 1 General Introduction 
1.1 Tumor formation 
Current annual death rates from malignant neoplastic diseases among over 70 
countries were found to be highly correlated with the percent of the population greater 
or equal to 60 years of age. Biological aging is an important intrinsic factor in cancer 
(Tallaride, 1995). Carcinomas are rare in persons under age 30, rising exponentially 
in incidence thereafter, and their appearance with increasing age emphasizes the 
importance of cumulative exposure of normal cells and tissues to environmental 
carcinogens, irradiation and viral infection. Normal cells have a finite life span so 
that they can only multiply for a certain number of cycles before they die. They also 
possess mechanisms like contact-inhibition and tissue-specific affinity to restrict the 
cell growth in number and location (Kuby, 1993(a)), but the major characteristic of 
cancers is their uncontrolled cell proliferation. 
Usually, the tumor cells are derived from a single neoplastic cell possessing a 
regulatory defect, which is inherited by the clonal progeny. The derangement in the 
cell cycle machinery contributes to indefinite cell growth. There may also be an 
alteration of cytoskeleton and morphology (Kuby, 1993(a)). They may also alter their 
tissue-specific affinity, so that they can grow beyond the boundaries of their tissue 6f 
origin and provide the basis for the dispersion of tumor cells to other sites of the body. 
They also alter their biochemical activities by increasing glycolytic activity, secretion 
of proteolytic enzymes to lyse the basement membrane and production of angiogenic 
factors. 
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Tumor progression in situ is usually accompanied by metastasis, which is the 
major cause ofrelapse after treatment and death. Metastasis begins with the secretion 
of protease from tumor cells to digest the extracellular matrix. As they pass through 
the matrix and reach the leaky endothelium, which is a characteristic ofnewly formed 
blood vessels induced by vascular endothelial cell growth factor (VEGF) (Roberts et 
a/, 1997)，they enter the circulation and reach other tissues and organs where they 
adhere to the endothelium, re-enter the extracellular matrix of the target tissues and 
organs, and then proliferate to become a tumor (Folkman, 1996). In this state, the 
tumor is said to be invasive or malignant. 
1.2 Anti-tumor pathways 
With the advent of cancer therapy, the 5-year survival rates are continuing to 
improve (Kearney, 1999), especially in leukemia and lymphoma (Spom, 1996). 
However, overall death rates from most of the common carcinomas have not reduced 
(Sporn, 1996). Current cancer therapeutic measures includes surgery, radiotherapy ” 
and chemotherapy. 
Surgery is the oldest and yet the commonest treatment for cancer. Particularly, 
surgery has moved into new areas like the use of fiber optic instruments which are 
minimally invasive (Kearney, 1999). The use ofsurgery is becoming less frequently 
as more precancerous lesions are identified and treated accordingly. 
Radiotherapy has also been used for over 100 years (Keamey,1999) and is still 
playing an important role in cancer therapy. Three-dimensional conformal 
radiotherapy, in which the final therapy volume conforms exactly to the shape of the 
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tumor, is now developing (Fuks et al, 1993) and it can give more precise treatment to 
the cancer. 
Chemotherapy is an extensively used cancer therapy which inhibits carcinogenesis 
by treatment of chemical compounds. Current chemotherapy can be briefly divided 
into 3 categories: 
(a) Cytotoxicity. This refers to direct killing of the tumor cells by the toxcitiy of the 
compound. 
(b) Anti-angiogenic therapy. This is interruption of new blood vessel formation, 
which in tum deprives the nutritive supply of the growing tumor and thus stops or 
slows down the tumor growth. 
(c) Immunoenhancement. The host defense system is up-regulated to fight against 
the tumor cells. 
1.2.1 Cytotoxicity 
Tumor cells possess immortality, usually by disrupting the cell division control 
“ 
mechanism which serves to stop the proliferation of abnormal cells in the body by 
arresting cell division and/or inducing apoptosis pFig. 1.1，adopted from Zymed 
Laboratories Inc.) 
A cell division starts at the entry of the cell from its resting GO phase into the G1 
phase. During the G1 phase, cells respond to extracellular signals by either advancing 
toward^S phase (DNA synthesis phase) or withdrawing from the cycle into a resting 
state (GO) (Sherr, 1994). G1 phase progression relies on stimulation by mitogens but 
can be blocked by antiproliferative cytokines and agents. After the cells pass the 
restriction point in G1 late phase (G1 checkpoint), they proceed to cell division. 
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Another restriction point is between G2 and M phase. Cell arrest at these checkpoints 
prevent DNA replication and mitosis in the unrepaired chromosomal alterations (Bunz 
et al., 1998). 
Cancer cells abandon these controls and tend to remain in cycle. (Sherr, 1996). 
Oncogenic processes exert their greatest effect by targeting particular regulators for 
G1 phase progression (Hall etal, 1996). The control of G1 phase passage involves the 
interaction of different cell cycle proteins. They are the cycIins, cyclin-dependent 
kinases (CDK), CDK inhibitors, and retinoblastoma tumor suppressor protein (Rb), 
etc. Briefly, binding of cyclins to CDKs phosphorylates Rb, which then allows the 
passage of G1 phase to S phase. The CDK inhibitors like p21 and p27 can restrict this 
process. The expression of p21 is in tum under the control of p53. The cell cycle 
restriction pathways are most frequently disrupted by Rb and p53 in tumor cells 
(Sherr, 1996); thus the cells can replicate infinitely. 
Therefore, anti-proliferation of the tumor cells is one the targets of cancer therapy. 
Current cytotoxic drugs against tumor cells usually non-specifically inhibit cell 
proliferation (Kearney, 1999) by interfering with nucleic acid or protein synthesis. 
II 
These include alkylating agents which cross-link DNA strands to prevent DNA 
replication and transcription ofRNA (Averbuch, 1990; Colvin et al, 1990; Reed et al, 
1990). Topoisomerase inhibitors like the plant alkaloid camptothecin and its 
analogues bind to DNA and topoisomerase enzymes, resulting in DNA damage that 
interferes with replication and transcription (Fischer et al, 1997). Mitotic inhibitors, 
e.g. vincristine, exert their cytotoxic effects by binding to tubulin, causing metaphase 
arrest. Antimetabolites, for example, 5-fluorouracil, interferes with pyrimidine 
synthesis by blocking thymidylate synthase, purine synthesis, and de novo protein 
synthesis, and by interfering with the synthesis of DNA. 5-fluorouracil is also 
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metabolized to the ribonucleotide triphosphate, fluorouracil triphosphate (FUTP), and 
is then incorporated into RNA, inhibiting its function (IgnofFo et al, 1998). 
A more specific cytotoxic therapy in development is gene therapy. Gene therapy 
is defined as a therapeutic technique in which a functioning gene is inserted into the 
cells of a patient to correct a genetic error or to provide a new function to the cell 
(Kearney, 1999). The reduction of cancer gene expression by antisense oligomers is 
an example of gene therapy OHelene et al, 1990), but cellular uptake and rapid 
degradation of the antisense oligomer are two major obstacles for routine clinical 
application (Carmichael, 1994). Once the current difficulties with gene therapy are 
overcome, gene therapy can be used in concert with other therapy like angiogenesis 
inhibitors to achieve a satisfactory effect. 
The accessibility of tumor cells to anti-cancer drugs is limited by high intersititial 
pressure of the tumor and multidrug resistance of the tumor cells (Jain, 1994). 
Moreover, most of the cancer drugs are cytotoxic to normal cells and they may cause 
many side effects (Carmichael, 1994). Current chemotherapy is thus shifted from 
conventional cytotoxicity to target-specific such as targeting the important enzymes 
for cellular proliferation or specific growth factor receptors on the cell membrane. In 
addition, analogue development is likely to produce drugs that may substantially 
reduce the toxicity associated with treatment (Carmichael, 1994). 
1.2.2 Anti-angiogenesis 
When the transformed cells escape from the regulatory machinery of the cell 
cycle, they multiply to form a tumor. As the tumor continues to grow, it requires 
more oxygen and nutrient supply from surrounding and infiltrating blood vessels. 
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The requirement of new blood vessel formation, a process known as angiogenesis, is 
crucial to tumor nourishment and progression (Folkman, 1972). His observation in 
the experiment of tumor growth in a perfused organ, with subsequent proof has 
confirmed the importance of tumor angiogenesis. It is now widely accepted that this 
process is critical in tumor progression. Fig. 1.2 shows the process of tumor 
angiogenesis (Folkman, 1996), which is not only vital to tumor growth in situ, but 
also a pre-requisite of metastasis. Therefore, anti-angiogenesis has now become a 
new target in cancer therapy ^^an et al, 1995). 
The process oftumor angiogenesis involves the interaction ofthe tumor cells, the 
endothelial cells and the extracellular matrix. Their interactions were mediated by 
adhesion of the tumor cells to the endothelium, and cytokines and growth factors 
secreted by the cells involved. Table 1 lists the major stimulatory and inhibitory 
factors in the process of angiogenesis. 
Table 1 Soluble factors involved in the control of angiogenesis (Querrec et 
al，1993). 
Inhibitory factors Stimulatory factors _ 
Thrombospondin (TSP) Acid/Basic fibroblast growth factor (FGF) ,' 
Plateletfactor4g>F4) Vascular endothelial growth factor (VEGF) 
Interferon-a (ffW-a) Platelet-derived endothelial cell growth 
factor (PD-ECGF)  
Interleukin-1 0L-1) Platelet-derived growth factor (PDGF) — 
Transforming growth factor-g (TGF-g) Transforming growth factor-3 (TGF-3) 
Protease inhibitors Angiogenin  
- Tumor necrosis factor-g CTNF-q) • 
Erythropoietin ^ P 0 ) 
Interleukin-4 and -8 (EL-4 and DL-8) 
There are several approaches of anti-angiogenic therapy and several anti-
angiogenic compounds are already in clinical trial (Table 1): 
(a) Inactivation ofangiogenic molecules. The activity ofangiogenic molecules can be 
neutralized by antibodies and antisense oligonucleotides. Barinaga (1997) has 
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slowed the growth and inhibited the activity of an angiogenic protein, VEGF, of 
several types of tumors in mice by antibody against VEGF. 
(b) Alteration of the protease/antiprotease balance. The tissue inhibitor of matrix 
metalloproteinase (TEVff) blocks the enzymes secreted by cancer cells that break 
down proteins of the extracellular matrix, enabling the tumor cells to slip through 
the surrounding tissue and spread. The same event occurs in the process of 
angiogenesis, and thus TEVEP can check tumor growth through anti-angiogenic 
pathway (Querrec et al, 1993). 
(c) Antagonists of angiogenic growth factor receptor. Integrin is a cell membrane 
receptor that allows endothelial cells to interact with a wide variety of 
extracellular matrix components, thus inducing cell migration and angiogenesis. 
The angiogenic activity can, however, be inhibited by binding of this adhesion 
receptor with its antagonists pLeavesley et al, 1993). 
(d) Inhibition of endothelial cells to stimuli. Compounds like angiostatic steroids, 
angioinhibins, PF4, etc., can inhibit other responses of endothelial cells to 
angiogenic stimuli (Querrec et al, 1996). 
II 
Table 2 Some angiogenesis-inhibiting drugs in clinical trials (Barinaga, 1997). 
Drug Mechanism Phase Trial (Cancer types) 
Marimastat Metalloproteinase inhibitor III (pancreatic, lung, brain) 
TNP470/AGM1470~~Analog of fumagillin, an anti- III (breast, Kaposi's � 
angiogenic fungal product sarcoma, cervical)  
Thalidomide Unknown II (brain, breast, prostate) 
CAI Calcium channel blocker I (wide range of cancers) 
EL-12 Induces anti-angiogenic protein I (kidney) 
n>-io  
Anti-angiogenesis is not only a novel approach of anti-tumor therapy, but it also 
has many advantages over conventional therapy: 
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(a) Conventional therapies usually target cancer cells, which are easy to mutate or 
develop resistance whatever the therapy is. Anti-angiogenesis targets at the 
normal dividing endothelial cells, which are less prone to mutate, and thus less 
easy to develop resistance (Barinaga, 1997). 
(b) It should be useful for many types of cancer because all tumor-feeding blood 
vessels are rather similar. 
(c) It is much easier to deliver the drugs to the endothelial cells that line the blood 
vessels than to every cell of the tumor mass (Barinaga, 1997). 
On the other hand, anti-angiogenic therapy also has its shortcomings: 
(a) Most of these compounds except angiostatin and integrin antagonist have not 
been shown to be effective against established tumors. Therefore, long-term 
treatment may be expected. 
(b) Since angiogenic inhibitors specifically inhibit neovascularization, anti-
angiogenesis treatment cannot be processed during embryonic development, 
endometrial regeneration and wound healing (Fan et al, 1995). 
These problems in anti-angiogenic therapy may be remedied by the combination 
“ 
of conventional therapy with it. By surgical removal of the primary tumor, anti-
angiogenics can be effectively administered to prevent metastasis. Once the growth 
ofmetastatic tumors can be limited by the anti-angiogenic agents, these tumors can be 
removed at a lower dose of cytotoxic drugs (Fan et al, 1995). Chemical modification, 
of the naturally occurred anti-angiogenic agents can further minimize their side 
effects. AGM1470, which is now in clinical trials phase III (Barinaga, 1997)，is a 
synthetic analogue of fumagillin, the side effect of which has been greatly reduced. 
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1.2.3 Immunomodulation 
The primary role of the immune system is to defend the host against the attack of 
foreign substances. The immune response of the tumor-bearing host towards the 
tumor involves a complicated interaction among the effector cells, the cytokines and 
the antibodies secreted by them. By the middle of this century two major hypotheses 
were advanced describing the role that the immune response might be playing in 
tumor growth (Manson, 1994): (a) immune surveillance theory (Bumet, 1970)，and 
(b) immunological enhancement theory (Kaliss, 1958). 
In the immune surveillance theory, the immune system is considered as a major 
defense system of the normal host, protecting itself against infectious microorganisms 
and tumors. Accordingly, autochthonous tumors that grow progressively are believed 
to be nonimmunogenic (weakly immunogenic); or the immune system has failed in its 
surveillance role so that the tumor is not rejected. In this concept, the T cell system is 
paramount and B cell responses are ignored. B cells ofthe tumor-bearing host are not 
making any anti-tumor response and therefore they have no role in influencing 
progressive tumor growth (Manson, 1994). 
In the immunological enhancement theory, the immune system works in concert 
with the operative system for tumor progression, resulting in antibody-mediated 
immunologic enhancement. It is found that the immune system responds initially to ' 
the tumor by secreting antibody, the isoform being IgM, which binds to the tumor 
specific surface antigen. The coating of tumor with IgM is not deleterious to the 
tumor cells and the tumor continues to grow. The tumor cells are found to be resistant 
to cytotoxic T cells after an early period of growth. It can be said that the tumor-
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bearing host has become fully immune to the tumor soon after the malignant 
transformation takes place (Manson, 1994). 
In the mediation of immune responses, cytokines play a very important role. 
Cytokines are a group of low-molecular-weight regulatory proteins secreted by 
leukocytes and a variety of other cells in the body in response to a number of inducing 
stimuli. Cytokines bind to specific receptors on the membrane of target cells, eliciting 
biochemical changes responsible for signal transduction that results in an altered 
pattern of gene expression in the target cells. Cytokines and their receptors exhibit 
very high affinity for each other with dissociation constants ranging from 10'^ ° to 10'^ ^ 
M. This means that cytokines can function at picomolar levels (Kuby, 1993(b)). 
Mosmann et al first reported (1986) that cloned murine helper T (Th) lymphoctyes 
could be divided into two functional subsets on the basis of the immunoregulatory 
cytokines they produced. Thl clones express interferon gamma (ffN-y), interleukin-2 
(EL-2) and tumor necrosis factor beta (TNF-P). 
Recent studies have concentrated on the effect of cytokines on differentiation o f T 
cells into Th-1 or Th-2 type (Schultze et al, 1999). It is believed that the nature ofthe 
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cytokine is a key factor in determining the nature of the immune response (Rincon et 
al, 1997). Some of these cytokines possess cross-regulatory properties such that they 
not only enhance on a type of clone and its cytokine production but also suppress the 
other type of clone and the cytokines that it produced (Lucey et al, 1996; Sornasse et� 
al, 1996; Rincon etal, 1997; Schultze et al, 1999). 
Current immunotherapy utilizes these different concepts in an attempt to up-
regulate the immune system against tumor progression. IL-2 and LFN-y are now in 
clinical use as anti-cancer drugs (Ballow et al, 1997). ]L-2 can enhance the cytotoxic 
function of lymphocytes, e.g. lymphokine-activated killer (LAK) cells, to many types 
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oftumor cells (Ballow et al, 1997). EFN-y can activate monocytes and macrophages. 
It can induce the expression of major histocompatibility complex (MHC) 
determinants on cells and augments the natural killer cells and antibody-dependent 
and T-cell-mediated cytotoxic effects (Ballow et al, 1997). These would result in 
enhancement in tumor cell killing by natural killer cells and cytotoxic T lymphocytes 
(CTL). It can also inhibit proto-oncogene expression to inhibit tumor growth 
(Kimchi, 1987). However, since these cytokines are pleuripotent, exogenous 
administration of these cytokines often elicit many side effects and require very 
accurate dosage control (Carmichael et al, 1994). The cross-regulatory properties of 
the type 1 and type 2 cytokines, together with the reversibility of the Th subclone cells 
may be beneficial for treatment of cancer (Somasse et al, 1996). More understanding 
about the type 1 and type 2 cytokine hopefully provide clues to restore the balance of 
cytokine secretion in the body against tumor progression. 
1.3 Aim ofProject 
•• 
Tumor progression in the body involves the unregulated division of tumor cells 
and the concomitant blood vessel formation to cope with increasing metabolic 
demand of the growing tumor. In response to the tumor growth, the immune system 
either plays an active role (immune enhancement) or a passive role (suppression of 
immune surveillance), though not clearly known yet. Thus, eradication of a growing 
tumor can be done through these different pathways. 
Preliminary results showed that a polysaccharopeptide, a component isolated from 
the fungus, Coriolus versicolor, possesses an anti-tumor activity in vivo, yet, the 
mechanism by which it exerts its effect against tumor growth is not known. Similar 
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phenomena have been reported on the up-regulation in immune system by other 
polysaccharides, but the underlying mechanism is not disclosed (Wang et al, 1995; 
Leung et al, 1997). Therefore, a series of experiments was designed in this study to 
investigate whether the anti-tumor activity of the polysaccharopeptide was mediated 
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Fig. 1.1 The cell cycle. The check points in between each phase 
are controlled by a combination of different cyclins, cyclin dependent 













































































































































































































































Chapter 2 In Vivo Antitumor Effect of Polysaccharopeptide 
2.1 Introduction 
A suitable animal model is essential to all in vivo studies, and mice have long been 
the experimental animal of choice. Mice are easy to handle, are genetically well 
characterized, and have a rapid breeding cycle (Kuby, 1993(c); Frey, 1997). 
To establish an animal model for tumor growth study, the first step is to induce 
tumor formation in the animals. Tumors can be induced either by administration of 
carcinogens (Kitahori et al, 1995), or inoculation of tumor cells, including 
subcutaneous, intramuscular, intradermal, and intravenous, (Begg, 1987) into the 
animals. Solid tumors can also be formed by xenograft transplantation (Keane et al, 
1998; Konaka et al, 1999), but ascites tumors are usually maintained in the peritoneal 
cavity. 
The site of implantation of tumors varies with specific purpose so as to minimize 
stress that would be caused during tumor development or drug treatment. Tumor is „ 
normally implanted at the back or the leg for local irradiation treatment because 
animals can be irradiated unanaesthetized and the tumor sizes can be measured easily. 
The flank also provides a convenient tumor growth site because it causes the least 
distress and inconvenience to the animal, hence it has been a good choice for' 
chemotherapy studies (Begg, 1987). There are several commonly used models for 
investigating tumor growth, and the advantages and disadvantages ofeach model have 
been compared by Siemann (1987) in Table 2.1. 
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Table 2.1 Comparison of advantages and disadvantages of difTerent tumor 
models. 
Spontaneous animal Early-generation Established~~tumor 
tumors transplanted tumors lines  
Advantages • Growth behavior • Availability of • Well 
similar to clinical replicate tumors characterized 
neoplasms • Growth behavior • Reproducible 
similar to clinical 
neoplasms  
Disadvantages • Few tumors • With • Little 
available transplanted- resemblance to 
• Poorly tumor-triggered tumor oforigin 




To establish appropriate tumor models, any possible artifacts that could influence 
the experiments should be eliminated, and the induction of an antitumor immune 
response in the host being one (Embleton, 1987). Immunogenicity can be reduced by 
the use of in vivo-in vivo cell transfers, or culturing the tumor cells in vitro in a 
medium containing homologous serum or in serum-free media (Lord, 1987). The 
experimental tumor cells can be maintained by storing early passage tumors in frozen “ 
aliquots. These frozen tumor cells will then be thawed for only a few passages for 
expansion and experimental use (Rockwell, 1987). 
Chemotherapy can be delivered at different sites, including intraperitoneal, 
intratumoraI, intravenous injection and oral feeding (Miura et al, 1995; Wu et al, 
1998). The duration of treatment is specific for each type of tumor and the 
experimental design, which depends on many factors like the growth rate of the 
tumor. 
The use of S180 cells for in vivo study has been well established. They can be 
studied in non-metastatic solid tumor form (Li et al, 1998; Wu et al, 1998) or in 
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ascites form (Wu et al, 1998). This tumor model has been used for drug screening 
(Cambanis etal, 1975), drug uptake and metabolism study (Li et al, 1998) and mostly 
the anti-tumor activity of different kinds of compounds (Keri et al, 1996; Chen et al, 
1998; Sato etal, 1998; Wang et al, 1998). In the sarcoma 180 solid tumor model, the 
period of treatment usually ranged from 21 days to 35 days in many other studies 
(Rumi et al, 1985; Chattopadhyay et al, 1986; Takatsuki et al, 1995; Miura et al, 
1998). Anti-tumor activity has been compared using parameters like tumor size (Guig 
" a / , 1997; Wang et al, 1998), tumor occurrence (Guig et al, 1997; Chen et al, 1998) 
and survival rate of the tumor bearing mice (Keri et al, 1996; Gupta et al, 1997). 
1.2 Materials and Methods 
1.2.1 Animal Model 
Preparation of polysaccharopeptide solution 
The polysaccharopeptide was isolated from deep-layer cultivated mycelia of „ 
Coriolus versicolor (Liu et al, 1993)，and it has a molecular weight of 100,000 dalton. 
The protein content of the polysaccharopeptide solution was measured by the method 
of Bradford (1976) and the amount of polysaccharopeptide used for the experiment 
was calculated as |ag protein/ml. ‘ 
Animal 
One hundred and sixty male inbred mice (BALB/c mice 6-8 weeks old) were used 
in this study. All the mice were supplied by the Laboratory Animal Service Centre 
(LASEC), The Chinese University of Hong Kong. The animals were housed under 
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normal laboratory conditions (21 土 2。。，12/12 h light/dark cycle) and maintained on 
standard rodent chow. 
Each mouse was inoculated with 1 x 10^ S180 cells subcutaneously at the back. 
Five days after inoculation, 80 mice were fed daily with the polysaccharopeptide 
solution in drinking water (35ng/day/mouse) (Liu et al, 1993). The other 80 mice 
receiving only drinking water served as controls. For simplicity, the 
polysaccharopeptide-treated group was called the treated group thereafter. Starting 
from Day 9 till Day 29，four mice from each group were killed for every five days. 
The body weight and the weight of the tumor were recorded. 
1.2.2 Statistical analysis 
The Mann-Whitney test was used to assess the significance in the difference in the 
body weight and tumor weight between the control and the treated group. In this test, 
the difference between the data of two different groups are considered significant 
when the exact significance (E.S.) is greater than the asymptotic significance (A.S.), ,' 
both ofwhich are generated by the software. All computations were done with SPSS 
Base 8.0 statistical software (USA). 
2.3 Results 
The body weight of the tumor-bearing mice did not change significantly (E.S. < 
A.S.) during the course of the tumor growth (Fig. 2.1). No death of mice was 
recorded throughout the course oftumor growth. 
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The tumor size varied greatly, even among the control groups not receiving any 
treatment. Table 2.2 shows the median, mean and standard error of mean values of 
the tumor weight. 
Table 2.2 The median, mean and standard error of mean (SEM) values of 
tumor weight on difTerent days. 
Day Control Group (g) Treated Group (g)  
Median (Mean ± SEM*) Median QSIean ± SEM*�  
Day 9 0.0470 (0.0629 ± 0.0129) 0.0361 (0.0477±0.0116)  
Day 14 0.1488 (0.1901 db 0.0607) 0.1255 (0.2005^0.0441) 
jygyl9 0.1708 (0.4065±0.1066) 0.1234(0.2372±0.0683)  
l>ay24 0 . 1 3 4 1 ( 0 . 4 1 7 8 ± 0 . 1 3 4 1 ) 0 . 0 8 4 5 ( 0 . 2 1 9 7 士 0 . 0 7 8 1 )  
^ay 29 0.6757 (0.7393 士 0.2036) 0.1820 (0.3862 士 0.1769^ 
*SEM stands for standard error mean. 
The tumor growth in the control group was statistically significantly greater than 
that in the treated group except on Day 9 (E. S. > A. S.) (Fig. 2.2). The growth of 
tumor in both groups was most rapid in the period between day 10 and day 15 after 
tumor inoculation. In the control group, there was another abrupt increase in tumor 
weight between Day 24 and Day 29. This was due to the presence of several large 
tumors. 
Comparing their difference in the mean values, the tumors in the control group on ” 
Day 29 was about 48% larger than that in the treated group. 
2.2 Discussion 
In this study, 6-8 weeks old mice were used because they are at the stage ofyoung 
adults with active metabolism. The use of male mice only eliminates the possible 
interference ofcyclic changes ofhormones in female mice. 
The tumor cells inoculated subcutaneously at the back ofthe mice were previously 
propagated for only 3 to 4 passages in the peritoneal cavity of the mice. The 
1 9 
advantage of using S180 cells is that these suspension cells grow rapidly in ascite 
form and allow easy manipulation when propagated in the peritoneal cavity. 
Propagating in vivo for a few passages reduced the immunogenicity ofthe tumor cells 
to the hosts. However, in vivo tumor sources would contain infiltration of host cells 
including stroma and immune cells, which may also introduce a complexity oftumor_ 
specific biological products (Frey, 1997). 
No metastasis was observed in all the experimental mice because S180 is a non-
metastatic solid sarcoma. Besides, had there been metastasis, the vital organ 
functions and metabolism, and thus body weight ofthe mice will be affected. 
The period ofstudy chosen (29 days) is in the range many other S180 solid tumor 
growth model used, and is supported by our preliminary study in which the mice 
began to die when the tumor cells were inoculated for more than a month. 
The choice of the site of inoculation is of importance in suiting different 
treatments, as well as influencing the outcome of primary tumor growth (Frey, 1997). 
Our preliminary studies showed that the tumors inoculated near the thorax grew most 
rapidly, but this posed difficulties in inoculation and manipulation in microcorrosion ,, 
casting. The tumors inoculated near the abdomen grew very slowly, most probably 
due to fewer blood vessel supplies. It took nearly double the time of the former to 
produce a tumor of similar size. Inoculation at the back has been chosen because 
tumor growth rate is intermediate between the two, with convenience in • 
microcorrosion casting operation. 
Our previous trial also showed that inoculated cells took about 5 days to develop 
into a solid tumor mass. If the feeding treatment started right after the inoculation, the 
polysaccharopeptide might interfere with the growth oftumor in a way different from 
the real situation. In human, treatment is always given only after the tumor is 
2 0 
detectable. Moreover, tumor growth was most rapid between Day 10 and Day 15. 
This may be in relation to the switching of the tumor from the pre-vascular stage to 
the vascular stage (Pepper, 1997). Macroscopically, tumors excised on Day 9 lacked 
vessels both within the tumor and in the stroma. In histochemical sections of these 
tumors, few blood vessels were stained by antibody against Factor Vni-related 
antigen (see chapter 4). The starting of treatment on Day 5 may be a good time point 
to investigate the polysaccharopeptide‘s intervention on angiogenesis. The 
husbandry of the mice is constant throughout the experiment. Stress was minimized, 
as the mice received no manipulation before they were killed for analysis. The 
polysaccharopeptide solution was given orally so that manipulation of the mice was 
minimized and the stress thus caused to them was reduced. 
The tumor weight varied greatly, even among the tumors in the control group. 
This may be due to an extreme degree of heterogeneity studies even in the same 
tumor entities, as reported in other studies (Steinberg et al, 1987). 
The weight of the tumors in the control group and in the treated group on Day 29 
differed by 48 % in mean values. Therefore, the polysaccharopeptide was shown to ., 
possess anti-tumor activity in the in vivo system. The inhibitory effect is relatively 
prominent when compared to other anti-tumor growth study in S180 solid tumor 
model with respect to dosage used and the percentage of inhibition. The 
polysaccharopeptide in this study was given at a dose of35^ig/mouse/day for 24 days 
by oral feeding. By the use of recombinant tissue inhibitor of metalloproteinase-3 
(rTIMP-3) at a dose of 20mg/kg body weight for 10 days (i.e. about 
500|ig/mouse/day, taking the average weight of the mouse as 25g), the inhibitory 
effect was 63.2% (Jianxin et al, 1998). Somatostain analogue TT-232 produced 
inhibition up to about 50% when given at 750^ig/kg body weight (i.e. about 
2 1 
18.75|igAnouse/day) (Keri et al, 1996). Red ginseng extract A and B produced an 
inhibitory effect of 47% and 45% respectively, at a dose of 400mg/kg body weight 
(i.e. about lOmg/mouse/day) by 10 days of oral feeding. In conclusion, the 
polysaccharopeptide has shown statistically significant inhibitory effect on the growth 




























































































































































































































































































































































































Chapter 3 Cytotoxicity 
3.1 Introduction 
Most anti-cancer drugs in current use inhibit cellular proliferation, and they were 
either isolated through large-scale drug screening programmes, or produced via 
analogue development (Carmichael, 1994). These agents can be categorized in Table 
3.1 according to their effect on the cell cycle. 
Table 3.1 Currently used cytotoxic anti-tumor drugs. 
Chemotherapy Actions Examples (Reference) 
agents  
Alkylating attack cancer cell DNA Cyclophosphosphamide 
agents (Ignoffo et al, 1998) 
Antimetabolities Interfere with cell function 5-fluorouracil 
(Ignoffo et al, 1998) 
Topoisomerase Inhibit DNA replication N-[2-(dimethylamino)ethyl] 
inhibitors acridine-4-carboxamide 
QBridewell et al., 1999) 
Antibiotics Bind DNA and prevent RNA Doxorubicin, mitomycin-C 
synthesis (Ignoffo et a i , 1998) 
Plant alkaloids Block cell division Vicristine, vinblastine 
(Plant derived (Ignoffo et al, 1998) , 
agents) “ 
Steroid Interfere with the growth of Tamoxifen “ 
hormones hormone-dependent cancer (IgnofFo et al, 1998) 
cells  
Spindle poisons Depolymerize microtubules Docetaxel (Eckardt, 1997) 
The anti-proliferative activity or cytotoxicity of these drugs can be assessed by * 
direct cell count, colorimetric measurement, fluorescent staining and ^[H]-thymidine 
incorporation method. They have different advantages and disadvantages, and they 
can provide different information on cell proliferation. 
Direct cell count is the most primitive, simple and accurate method in assessing 
cytotoxicity, trypan blue exclusion method being the typical example (Ren et al, 
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1999). Under light microscope, viable cells exclude the dye while dead cells are 
stained dark blue. This method requires a substantial amount ofcells to make the test 
reliable and demands high labor-input. 
Common colorimetric assays include crystal violet staining (Klostergaard et al， 
1996)，MTT assay (Schweikl et al, 1996), and neutral red staining (Schweikl et al, 
19%). All these dyes are taken up by the cells in a certain way and later solubilised 
and quantitated spectrophotometrically. All these methods are more favorable with 
adherent cells because before solubiIisation, the medium together with excessive dye 
has to be removed. Application of these methods to loosely adherent or suspension 
cells easily introduce variations in measurement. 
Crystal violet staining is a simple method for measuring cytotoxicity especially 
for adherent cells. It only stains those cells that are still adherent after washing. The 
assumption is that for adherent cells, the dead cells are detached and removed; only 
the live cells remain and are thus stained. It has been, however, observed under the 
light microscope that different cells of the same population have different 
stainabilities. This may be attributed to the difference in membrane structure or 
chemistry, especially after treatment. 
The MTT assay is based upon the ability of living cells to reduce MTT, 3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, into formazan. The validity 
ofthe MTT assay depends on the assumption that only viable cells reduce tetrazolium * 
salts to colored formazan (Mosmann, 1983). Neutral red ONK) staining is based on the 
/•« vitro incorporation of a supravital dye, neutral red, into lysosomes of living 
mammalian cells (Borenfreund et al, 1984). The colored product can then be 
solubilised and quantitated spectrophotometrically. 
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Apart from colorimetric assays, fluorescent staining has become more popular in 
cell proliferation assay. Since some newly discovered fluorescent dyes can quantitate 
DNA down to nanogram levels, the binding of fluorescent dyes to DNA can provide 
an accurate estimation of cell number. It is an easy and simple way of measuring cell 
proliferation by using fluorescent dyes, e.g. Hoechst 33243 (Reisenbichler et al, 1996; 
Gothot et al 1998)，2',7'-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) 
(Sellers et al, 1994), etc. Ifi t is used for adherent cells, cytotoxicity can be measured 
by removing the dead cells before addition of fluorescent dye. However, this method 
can only provide the number of cells in the culture but not distinguish cytotoxic from 
cytostatic effect of the drug to suspension cells. Furthermore, quenching and auto-
fluorescence of some drugs may limit the use ofthis method. 
The most traditional method of measuring cell proliferation is the ^[H]-thymidine 
uptake method. The incorporation of radioisotope-labeled thymidine into the genome 
ofproliferating cells provides a very sensitive method, which is suitable for any kind 
of cells. However, it can only show anti-proliferation, but cannot distinguish 
cytotoxicity from cytostasis. The use of radioisotope also makes it less favorable. 
“ 
In this study, the effect of the polysaccharopeptide on tumor cell proliferation was 
studied using ^[H]-thymidine uptake method and Hoechst 33243 staining method. A 
combination of these two methods can provide an accurate assessment of anti-
proliferative activity, including cytotoxic and cytostatic effects of the * 
polysaccharopeptide on mouse sarcoma S180 cells and splenocytes. 
2 5 
3.2 Materials and Methods 
Cellline 
S180 cells (ATCC Tffi66, USA) were maintained in DMEM O^ife Technologies, 
USA) supplemented with 10% FBS (Life Technologies, USA) and lOO^g/ml 
streptomycin and lOODJ/ml penicillin at 37�C in a humidified atmosphere of5% CO2. 
The proliferation assay was performed using Hoechst 33243 (Molecular Probes, 
USA) and [^]-thymidine (Amersham Pharmacia Biotech, UK). 
Proliferation assay 
(a) 3[H]-thymidine incorporation assay 
The S180 cells (2 x 10^  cells/50^1/well) were seeded into a 96-well culture 
plate and serial dilutions of 50 i^l polysaccharopeptide to make a final 
concentration ranging from 1600^ig/ml to O.Ol^ig/ml. The control contained 
medium only. After incubation of the cells at T f C in a humidified atmosphere of 
5% CO2 for 18 hours, 10^1 [^]-thymidine at a dilution o f l :20 (stock solution at 
the concentration of lmCi/ml) was added, and the cells were incubated for a “ 
further 6 hours at the same conditions. The cells were then harvested with an 
automated cell harvester onto a glass filter, and the radioactivity was measured 
with a Beckman model LS 6000SC scintillation counter. All reported values are 
the means of triplicate samples. 
(b) FIuorometric analysis ofDNA 
The proliferation of S180 cells was also assessed by staining cellular DNA 
with Hoechst 33243 (Reisenbichler et al, 1996). The cells were cultured with 
treatment as stated above. 24 hours after treatment, 75^il of medium was 
removed. The cells were frozen and then 100^1 double distilled water (ddH2O) 
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was added. The cells were frozen again and thereafter lOO i^l of Hoechst 33243 
solution at a concentration of 20^ig/ml was added. After 5 minutes of incubation 
at 37°C, it was taken for fluorescent reading by Cytofluo 2350 (Millipore, USA) 
For the proliferation of murine splenocytes, three BALB/c mice (8 weeks old) 
were killed by cervical dislocation and the spleens were aseptically removed. Spleen 
cells were isolated by pressing the tissue through a sterilized 100-mesh stainless steel 
sieve and resuspended to 1 x 10^  cells/ml in RPMI 1640 culture medium (Sigma, 
USA) supplemented with 10% FBS, lOORJ penicillinAnl and lOO i^g streptomycinAnl. 
The cells (5 x 10^  cells/50|iI/well) were seeded into a 96-weIl culture plate and serial 
dilutions of 50^il of the polysaccharopeptide ranging from 1600^g/ml to O.Ol^ig/ml 
were added. After incubation of the cells at 37�C in a humidified atmosphere of 5% 
CO2 for 48 hours, the proliferation of the spleen cells was assessed by the Hoechst 
assay as described above. 
The percentage of proliferation was calculated as below: 
Percentage of proliferation = (S/C) *100% 
•仪 ^ = average countsper minute ffluorescent reading) from the treatedsamples “ 
C = average countsper minute (fluorescent reading) from the control 




With the use of the ^[H]-thymidine-uptake assay, the treatment of 
polysaccharopeptide up to 200^g/ml did not affect the proliferation of S180 cells as 
compared to the control (Fig. 3.1). Above the high concentration of 200ng/ml 
polysaccharopeptide, there was an abrupt drop ofthe percentage ofproliferation. 
With the use ofHoechst 33243，the results were similar for the range ofO.Ol^ig/ml 
to 23.4|ig/ml (Fig. 3.2). Beyond 23.4^ig/ml, an increase offluorescence reading was 
obtained, which might be due to autofluorescence of the polysaccharopeptide. 
For the proliferation of splenocytes, the polysaccharopeptide exerted no cytotoxic 
effect on the murine splenocytes fFig. 3.3) at concentrations up to lmg/ml. 
3.4 Discussion 
S180 cells have long been used for screening the anti-tumor activity of certain 
compounds (Lou et al, 1994; Moritiani et al, 1996; Rekonen et al, 1997; Mizuno et al, “ 
19卯). In the present study, the polysaccharopeptide has shown no cytotoxicity 
towards S180 cells at concentration below 200^xgAnl. At concentrations beyond 
23.4^ig/ml, results from the two assays showed discrepancies. The Hoechst assay 
showed increase of DNA fluorescence while the ^[H]-thymidine-uptake decreased 
dramatically. The ^[H]-thymidine-uptake method recorded the amount of thymidine 
taken up by the cells for replication and the decrease of thymidine uptake indicated 
polysaccharopeptide at doses higher than 200^ig/ml exhibited anti-proliferative 
activity. Therefore, when cytostaticity is induced, the percentage ofproliferation from 
3 • • 
[H]-thymidine-uptake method would be much lower than the reading from the 
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Therefore, when cytostaticity is induced, the percentage of proliferation from ^[H]-
thymidine-uptake method would be much lower than the reading from the Hoechst 
assay, which measured the amount of fluorescent DNA from both dead and alive 
cells. Moreover, our unpublished data indicated that as the concentration of the 
polysaccharopeptide increased, autofluorescence from the polysaccharopeptide 
interfered with the fluorescence reading, implying that the increase level of 
fluorescent DNA may be an artifact. However, such a high concentration of 
polysaccharopeptide normally would not be encountered under physiological 
conditions because the concentration of polysaccharopeptide in the drinking water 
was much lower (11.43^ig/ml). 
From the in vitro study, the polysaccharopeptide showed inhibition ofS180 cells 
at high doses, which were however, much higher than that given to the mice. 
Moreover, the polysaccharopeptide showed no cytotoxic effects on the proliferation 
of murine splenocytes even up to lmgAnl. Therefore, the polysaccharopeptide may 




































































































































































































































































































































































































































































Chapter 4 Anti-angiogenic Effect 
4.1 Introduction 
Different experimental models have been proposed for the study of angiogenesis: 
/« vivo methods include the rabbit ear chamber (Ichioka et al, 1998)，hamster cheek 
pouch (Sekiya et al, 1986), rat corneal micropocket ^"rater-Schroder et al, 1987), and 
the chick embryo chorioallantoic membrane (Leibovich et al, 1987), and in vitro 
methods use cultures of human or animal endothelial cells from macro- or micro-
vessels (Dimitroff et al, 1999; Lozonschi et al, 1999). Although endothelial cell 
culture provides a useful tool for the study of cell migration, proliferation and 
secretion (Querrec et al, 1993), the heterogeneity of endothelial cell subpopulations 
from different sources provides confused information (Swerlick et al, 1992; 
Haraldsen et al, 1996; Shyjan etal, 1996; Jahnsen et al, 1997). Moreover, in vitro 
culture may not be comparable to the interaction of different factors and cells in the 
real microenvironment of the in vivo system, and sometimes, opposite results would •‘ 
be observed (Pintavorn，1997). An in vivo model has been used in the present study 
to investigate the anti-angiogenic activity of the polysaccharopeptide. Several 
methods including microcorrosion casting, immunohistochemistry and gene 
expression ofangiogenic factors were used to elucidate its underlying mechanism. ‘ 
4.1.1 Microcorrosion casting 
The vasculature of the tumors plays an important role in tumor progression, and 
the use of microcorrosion casting enables us to study the architecture of these blood 
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vessels. This technique has several advantages over the traditional three-dimensional 
reconstruction from immunohistologicaI sections. Practically, it is much less 
laborious. It can clearly demonstrate the whole terminal blood stream from the arterial 
to the venous segments including the capillary bed (Konerding, 1991) (Plate 4.1). The 
modes of branching and varying vascular densities can also be shown in the cast 
(Konerding, 1991). It allows identification of different types of blood vessels 
according to the surface features of the cast and determination of the direction of 
blood flow according to the arrangement of arteries and veins (Konerding, 1991). 
However, artifacts produced by incomplete filling and artificial thrombi represent the 
major drawback ofthis method and result in a lower vascular density. Pretreatment 
and flushing with heparinisation is therefore essential to produce a vascular corrosion 
cast for both qualitative and quantitative analysis. 
4.1.2 Immunohistochemistry 
Since angiogenesis is very important to tumor progression, it has been considered „ 
as a prognostic factor to evaluate tumor growth, especially for those highly 
vascularized cancer like breast cancer (Costelio et al, 1995; Fox et a!，1995; Goulding 
et 喊 1995; Charpin et al, 1997; Fox, 1997)，the growth and metastasis ofwhich are 
highly correlated to tumor vascularity. ‘ 
There are numerous methods for evaluating angiogenesis, usually involving the 
assessment of tumor sections after immunostaining of blood vessels with antibodies 
against CD31，CD34 and Factor Vffl-related antigen (Kuzu et al, 1992). 
CD31 is a platelet endothelial adhesion molecule p^ECAM) which is a more 
sensitive marker than Factor Vm_related antigen for endothelial cells (Horak et al, 
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1992). However, CD31 is not only specific for endothelial cells but also for plasma 
cells and myelomonocytic cells (Weidner et al, 1993). Its antigenicity will lose 
during fixation with acetic acid (Vermeulen et al, 1996). Factor VXH-related antigen 
and CD34 identify only a proportion of vascular endothelial cells and will therefore 
underestimate the true extent of the microvasculature (Ogawa et al，1994; Simpson et 
a l 1994). In spite of this, both Factor VHI-related antigeri and CD31 staining provide 
prognostic information (Toi et al, 1993). 
There are several methods in assessing tumor vascularity: 
(a) Observer subjective vascular grading - tumor vascularity can be assessed through 
the subjective appraisal by eye of immunohistochemically highlighted 
microvesseIs to determine the vascular grade (Fox et al, 1995). 
(b) Manual counting method - the vascular density evaluated by counting and 
calculating the immunostained blood vessels manually under the light microscope. 
(c) Chalkley count method - a 25-point Chalkley point eyepiece graticule was 
superimposed over the highly vascularized areas of the tumor sections and the 
number was recorded and used for statistical analysis (Fox et al, 1995). 
(d) Computer assisted image analysis - it provides the automated evaluation of more 
parameters like vessel number, vessel areas, positively stained areas in pixels, etc. 
(Fox et al, 1995;Kohlberger et al, 1996). 
4.1.3 Gene expression of angiogenic factors 
The process of angiogenesis is mediated by a wide spectrum of factors called 
angiogeneic factors. They can be separated into two categories: 
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(a) Direct angiogenic factors - act directly on vascular endothelial cells to stimulate 
locomotion or mitosis. 
(b) Indirect angiogenic factors - act indirectly by mobilizing host cells, e.g. 
macrophages, to release endothelial growth factors. 
The process of angiogenesis is most active in embryogenesis, but most of the 
endothelial cells in adults are quiescent (Engerman et al, 1967) except in areas where 
physiological angiogenesis occur, e.g. menstrual cycle in the ovary, wound healing, 
etc. On the other hand, angiogenesis is related to many pathological conditions like 
rheumatoid arthritis, retinopathy, and tumor progression (Folkman, 1995). 
Expression of the vascular endothelial cell growth factor (VEFG) has been 
demonstrated in many types of developing solid tumors (Boocock et al, 1995; 
Hashimoto et al, 1995; Femando et al，1997; Yamaguchi et al, 1998), and antibodies 
directed against VEGF were shown to inhibit tumor growth through the inhibition of 
tumor angiogenesis (Kim et al, 1993), indicating the importance ofVEGF. 
VEGF is a well-characterized angiogenic regulator which has five isoforms, 
consisting of 121，145, 165, 189 and 206 amino-acids (VEGF121-206) produced by 
alternative splicing of VEGF mRNA (Tischer et al, 1991; Kozlowska et al, 1998; 
Tomisawa et al, 1999). VEGF121.i65 are secretory proteins while the two longer VEGF 
forms are cell associated (Houck et al, 1992). The two cell-associated forms have not 
been purified yet and thus their functions are not clearly known. VEGFs have 
different binding affinities to their receptors, mostly attributed to their different 
binding affinities to heparin (Cohen et al, 1995), yet they have similar biological 
functions. They do not only stimulate the proliferation of endothelial cells (Shibuya, 
1995)，but also increase vascular permeability (Shibuya, 1995; Roberts et al，1997)， 
up-regulate expression of interstitial coIlagenase O^nemori et al, 1992) and hexose 
� 
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transporter GLUT-1 genes in endothelial cells (PekaIa et al, 1990), and induce the 
release of von Willebrand factor (Factor VXH) from Weibel-Palade bodies by 
endothelial cells (Brock et al, 1991). It has also been shown as a chemotactic factor 
for peripheral blood monocytes (Clauss et al, 1990). 
VEGF stimulates the endothelial cells lining nearby microvessels to proliferate, to 
migrate, and to alter their pattem of gene expression. VEGF also renders the same 
microvascular endothelium hyperpermeabIe so that it spills plasma proteins into the 
extravascular space, leading to the clotting of extravasated fibrinogen with deposition 
of a fibrin gel. The formation of a fibrin gel favors and supports the ingrowth of new 
blood vessels and other mesenchymal cells that generate mature, vascularized stroma 
(Dvorak et al, 1995). The fact that among all the angiogenic factors identified so far, 
only VEGF increases vascular permeability directly, and that all the new blood 
vessels are hyperpermeabIe, implying that other angiogenic factors may mediate their 
action through the up-regulation ofVEGF expression (Dvorak et al, 1995). 
VEGF, together with other angiogenic factors like basic fibroblast growth factor 
(bFGF), transforming growth factor beta (TGF-p), etc. can also decrease the 
inflammatory response of tumor-associated endothelium by upregulating endothelial 
adhesion molecules. In this way, they impair the adhesion of lymphocytes to the 
endothelium which otherwise would transmigrate to the tumor and mediate 
cytotoxicity on the tumor cells (Griffioen et al, 1996). * 
The action ofVEGF is mediated through two tyrosine kinase receptors, t h e f m s -
like tyrosine kinase-1 (flt-l) and fetal liver kinase-1 (flk>l) or the kinase insert 
domain-containing receptor (KDR), the human form of flk-1 and more recently 
identified flt-4. The expression of these receptors also contributes to the activity of 
VEGF. 
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Up-reguIation of VEGF is often found in tumor cells, both in cell lines and solid 
tumors (Boocock et al, 1995). Many studies have claimed that hypoxia up-regulates 
the expression of VEGF and its receptors (Iizuka et al, 1994), a condition that often 
occurs in the inner region of the tumor, particularly in tumor cells next to the necrotic 
region (Plate et al, 1994). However, this hypoxia-induced VEGF expression was 
several folds less than that in cell culture in contrast" to a more prominent up-
regulation offlt-1 in the tumor. Therefore, the up-regulation of mitogenic activity in 
response to hypoxia may be mediated by increasing flt-1 expression (Sandner et al, 
1997). VEGF is also up-regulated by other cytokines, such as TGF-P (Brogi et al, 
1994; Pertovaara et al, 1994; Pintavorn, 1997)，TNF-a (Paleolog, 1997; Ryuto et al, 
1996; Samaniego etal, 1998) and EL-1 (Paleolog, 1997). Similarly, the expression of 
VEGF receptors can also be up-regulated by cytokines (Pintavom, 1997). The 
expression of both VEGF and its receptors on the surface of tumor cells plays an 
important role in the pathogenesis of both benign and malignant vascular tumors 
(Hashimoto etal, 1995;Brown etal, 1996). 
“ 
4.2 Materials and Methods 
4.2.1 Microcorrosion casting 
Preparation of corrosion cast 
The microcorrosion cast was performed according to the method provided by 
Konerding et al (1989). Briefly, the animals were thoracotomized in deep 
chlorohydrate anesthesia (7%, 0.5mI/100g body weight i.p.) 20 minutes after an 
intraperitoneal application of heparin (500KJ/100g body weight, Sigma, USA). 
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Administration ofheparin prevented the formation of thrombi and blood clotting. An 
olive-tipped cannula was inserted into the left ventricle through which up to 20ml of 
body warm saline was perfused to rinse the vascular system free of blood before the 
tumor together with the animal was fixed by perfusion with a total of 20ml of body 
warm glutaraldehyde solution (2.5% phosphate-buffered glutaraldehyde, pH7.4). 
Mercox CL-2B® diluted with methylmetacrylate (4:1) was used as casting medium. 
Each animal was perfused with about 10ml of diluted Mercox. The tumors were 
removed after hardening in warm water (�40�C)，and the tumor tissues were corroded 
in 10% potassium hydroxide (KOH) solution at 40�C. Fresh KOH solution was daily 
replaced until the cast was clear of tissues when examined under the dissecting 
microscope. The casts were then cleaned with gradual sucking away ofKOH solution 
and adding of distilled water, before they were frozen in water and cut in required 
orientation as ice tissue blocks. The casts were then dried in a lyophilizer and 
mounted by the "conductive bridging" method on the metal stubs with many pieces 
of thin copper wires (Lametschwandtner, 1992). The casts were coated with 
palladium-gold at 25mA for 30s for 5 times, with argon flush at intervals. The 
“ 
specimens were then ready for scanning electron-microscopic study. 
Scanning electron-microscopy of microcorrosion casts 
SEM pictures of the microcorrosion casts were taken with a scanning electron 
microscope (JSM 6301F, JeoI) using a magnification between 25x and 500x at arT 
acceleration voltage of3kV and a working distance about 15mm. Three casts from the 




Tumors excised from the mice were fixed in 4% paraformaldehyde (phosphate-
bufFered, pH 7.4) at room temperature overnight, dehydrated, embedded in paraffin 
wax and sectioned at 7 i^m thick before staining with haematoxylin-eosin and antibody 
against von WiIlibrand Factor (Factor VIII). 
Paraffin sections were soaked in xylene to remove paraffin and rehydrated in 
graded alcohol series (100% to 70%). The endogenous peroxidase activity was 
inhibited by incubating in 3% H2O2 for 10 minutes at room temperature before they 
were washed in phosphate buffered saline (PBS) and incubated in trypsin (Sigma, 
USA) for another 10 minutes at 37�C. After digestion, they were washed with 
PBS/FBS (phosphate buffered saline containing 10% FBS) for 3 times, 2 minutes 
each. The sections were incubated with monoclonal antibody against Factor VIE-
reIated antigen (diluted in PBSA^BS at a ratio ofl:200) (Dako, Denmark) for 3 hours 
at room temperature. The sections were then washed briefly with FBS/PBS, incubated 
1/ 
with biotinylated goat anti-rabbit antibody and coated with streptavidin conjugated to 
alkaline phosphatase for 30 minutes. The sections were then rinsed in PBS for 5 
minutes, incubated with AEC chromogen (Zymed, USA), and finally counterstained 
with haematoxylin and mounted in glycerol. A negative control was prepared for each 




The image analysis was performed according to the method described by 
Kohlberger et al (1996) ^>late 4.2 (a)-(d)). Briefly, one section from each tumor 
block was chosen for analysis. The image was captured by the imaging system which 
consists of a cooled color digital (CCD) camera (Spot, Universal Imaging Corp., 
USA) and a light microscope (Axiophot, Zeiss, Germany). Under the microscope, 
four most highly vascularized areas known as the 'h ot spots， (Weidner et al, 1991), 
f> 
each of0.25mm，were chosen at 100x magnification for evaluation. Any red-staining 
endothelial cell or endotheIial-cell cluster that was clearly separated from adjacent 
microvessels, tumor cells, and other connective-tissue elements was considered as a 
single, countable microvesseI. Vessel lumens and red blood cells, although usually 
present，were not necessary for consideration as markers for microvessels (Weidner et 
al, 1991). 
Evaluation of captured image was done by the software Metamorph™. The 
positively stained blood vessels were then outlined manually by using the "Region 
Tools". The number of vessels was counted and the area enclosed by the vessels was 
“ 
calculated. Eighteen and fifteen sections from the control group and the treated group 
respectively were examined. The figures were then used to calculate vascular density 
in number ofblood vessels in lmm^ and also in % area enclosed by the blood vessels. 
The relationship between tumor growth and vascular density was assessed. -
Statistical analysis 
The Pearson，s test was used to evaluate the significant correlation between (i) the 
number ofvessels per unit area and the tumor weight, and (ii) the area of vessels per 
unit area with the tumor weight. Correlation is considered significant when p<0.001. 
All computations were done with SPSS Base 8.0 statistical software (USA). 
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4.2.3 Gene expression of angiogenic factors 
Spleens were homogenized in RNA extraction buffer on ice and total cellular 
RNA was isolated according to the method of Chomczynski et al (1987). 
All the reagents for the reverse-transcription polymerase chain reaction (RT-PCR) 
were purchased from Life Technologies, USA. Oligo(dT)-primed cDNAs were 
prepared in a volume of20 i^l from 1 ^g of total RNA using SuPERScmPT™ II RNase 
free reverse transcriptase. PCR was carried out in a 25 i^l mixture using the PCR 
Reagent System. The primer sequence, amplification temperature, time, number of 
reaction cycles and the size of the PCR products are shown in Table 4.1. 
The amplified products were separated and analyzed by 1.2 % (w/v) agarose gel 
electrophoresis, and their intensities were quantified by the software ImageQuant and 
normalized with P-actin. 
4.2 Results 
” 
4.3.1 Microcorrosion casting 
The tumor was induced by subcutaneous inoculation ofmouse sarcoma S180 cells 
into the mice. In the subcutaneous space, the vasculature between the tumor border 
and normal host tissue represented a true transition from normal non-proliferating 
host vessels to tumor vessels generated in response to secreted, diffiisible angiogenic 
growth factors like VEGF. Their morphology was in between the tortuous vessels in 
the tumor core and the straight course of normal vessels. Normal vessels had an even 









































































































































































































































































































































































































































































extended to the tumor (Plate 4.3(a)) and formed a vascular tumor envelope (Grunt et 
a/, 1986) OPlate 4.3(b)). The expanding tumors also enclosed some of the muscle 
fibres, which were seen in both scanning electron micrographs and light micrographs 
(Plate 4.4). The muscle fibres were finally deprived of nutrition by the rapidly 
growing tumor and degenerated, which were proved by the regressing vessels of the 
muscle in the SEM picture (Plate 4.5(a)) and the pale eosin staining in light 
microscopic image (Plate 4.5(b)). 
The tumor vasculature is composed of a dense vascular network of highly varying 
densities. Densely vascularized regions accompanied by avascular regions are 
frequently observed (Plate 4.6(a)). This was consistent with the observation of the 
results from tumor sections immunostained with antibody against Factor VHI pPlate 
4.6(b)). 
At the core of the tumor, the vasculature was more chaotic with abundant 
structures like tumor sinusoids (Plate 4.7), glomeruloidal arrangement of vessels 
(Plate 4.8) and new sprouts seen as plump protrusions and bulges (Plate 4.8). 
When the tumors of the control group were compared with those in the treated 
•• 
group，several differences were observed. Macroscopically, the casts from the treated 
tumors possessed fewer blood vessels, as well as at a lower density observed by bare 
eyes. When examined under the scanning electron microscope, fewer dilated vessels 
with meandering courses were observed at the periphery o f the tumors in the treated 
group. Their tumor vascular envelope was also less well developed than that in the 
control group. They were mostly surrounded by vessels of muscle fibres or 
subcutaneous tissue, which appeared to be normal in structure. 
At the core o f the tumor, more drastic differences were observed. The tumors in 
the control group contained abundant tumor sinusoids, which formed a mesh-like 
4 0 
network and extended throughout the tumor centre ^Mate 4.9). Tumors from the 
treated group did contain sinusoids or gIomeruloidaI structures, but in a more sparsely 
distributed pattem ^Mate 4.10). Plate 4.11 shows that most of the vessels are of 
muscle fibres, while those nodules (Plate 4.12) implying active angiogenesis are only 
scattering at different portions of the cast. 
4.3.2 Immunohistocheniistry 
A positive linear relationship was observed when the number of vessels counted 
was plotted against the tumor weight (Fig. 4.1). By the Pearson's test, the correlation 
of the number of vessels per unit area versus the tumor weight was considered 
significant (p<0.001). The blood vessel count was higher in the control group, and so 
was the tumor weight (Fig. 4.1). 
The area of the blood vessels was not significantly (p>0.001) correlated with the 
tumor weight, because their distribution was more diverse (Fig. 4.2). 
“ 
4.3.3 Gene expression of angiogenic factors 
The level of VEGF expression in the control group was generally much higher 
than that of the treated group (Fig. 4.3(a)). The expression of Flt-1 in the control� 
group increased from Day 9 to Day 19 and then remained constant thereafter. In the 
treated group, the expression ofFlk-l was similar from Day 9 to Day 24, and declined 
on Day 29 (Fig. 4.3 (b)). 
The expression ofFlt-1 increased with time in both groups, and the level was 
slightly higher in the treated group (Fig 4.3 (c)). 
4 1 
4.4 Discussion 
Tumor angiogenesis is an important factor for the progression of tumor, thus, 
tumor growth inhibition resulting from anti-angiogenesis should be revealed in a 
change in tumor vasculature. 
Microcorrosion casting has long been used to study the tumor vascularture of 
different tumors like melanoma, colonic adenocarcinoma, Lewis lung carcinoma, 
angiosarcoma, and leiomyosarcoma, etc. (Konerding et al, 1995). Recent 
development in this field has enabled scientists to compare the effect of a drug 
treatment on the vasculature, especially those angiogenic factors on tumor vasculature 
(Konerding et a/, 1998). 
From the results ofthe microcorrosion casting in the present study, differences in 
the architecture ofthe blood vessels were observed. The casts from the control group 
showed more features of active neovascularization like the dense network of tumor 
sinusoids in the core of the tumor, meandering vessels at the periphery, and leaky 
vessels. These features matched with other documented findings about angiogenic-
factor-induced changes in tumor vasculature. VEGF caused fenestrations in 
endothelium and opened interendothelial junctions, thus producing leaky 
hyperpermeable vessels ^Dvorak et al, 1995; Roberts et al, 1997)，which were shown 
by the existence of abundant extravasates in our SEM pictures (Plate 4.13(a)). 
Though extravasates may result from the blowing off of vessels during perfusion, 
such possibility could be excluded by the quality of the casts examined under the 
scanning electron microscope. Another proofof the leaky vessels was shown in light 
microscope images, where red blood cells were seen dispersed among the tumor cells, 
with no defined border of the endothelium (Plate 4.13(b)). This should not be an 
4 2 
artifact during processing or sectioning because such phenomenon was not seen in 
blood vessels with well-defined endothelium. 
The extent to which the growth factors were affecting the tumor could also be 
deducted from the morphology of the blood vessels at the periphery because the 
morphology of these preformed vessels in the subcutaneous space was affected by the 
growth factors diffusing out from the tumor cells. The. fact that the tumors in the 
control group showed more tortuous vessels implies that they were under greater 
influence of the growth factors. In conclusion, a higher level of angiogenic factors 
influenced the tumors from the control group. 
The study of the relationship between vascular density and tumor weight once 
again proved the importance of angiogenesis to tumor growth. Clear correlation was 
demonstrated in the number of vessels with the tumor weight. 
The rationale for assessing microvessel density in selected areas compared to an 
overall vascular count is manifold. From a practical point of view, given the 
intratumoral heterogeneity, obtaining a reproducible overall assessment of 
microvessel density implies the evaluation of large tumor areas and more work. From 
“ 
a pathophysiological point of view, it might be expected that the mechanism 
responsible for the direct and indirect relations between the tumor and the endothelial 
cell population is particularly active in those highly vascular regions (Vermeulen et 
al, 1996). . 
The relationship between the area of the blood vessels and the tumor weight was 
less consistent. This may be due to the shrinkage and collapse of the blood vessels 
during processing, making the data in area less reliable for evaluation. 
Offset values of irrelevant vessel counts in relation to tumor size were found in 
two samples from the treated group and one in the control group. All of them were of 
4 3 
high tumor weight. This might arise from sampling errors because only one section 
was taken from each tumor block, and the tumor vasculature was highly heterogenous 
(Weidner et al, 1991). This is already shown in the microcorrosion casting. 
Consequently, these three points were excluded in both graphs. 
The results from the microcorrosion casting and the immunohistochemicaI 
staining showed that the tumor vasculature was highly related to the tumor 
progression and that in the treated group, the tumor vasculature possesses less active 
angiogenic features. 
The gene expression study further confirmed the anti-angiogenic effect of the 
polysaccharopeptide. The expression ofVEGF was much lower in the treated group. 
Since VEGF is a key factor in angiogenesis, its down-regulation was sure to produce 
a much lower stimulatory effect on tumor angiogenesis, which strongly agreed with 
the morphological observation in the present study. The expression of the VEGF 
receptors, the fIt-1 and flk-l, was less consistent. The level off l t -1 was similar and 
gradually increased along tumor progression. On the other hand, the flk-1 expression 
is negatively correlated with VEGF expression. The VEGF level was higher in the 
“ 
control group while flk-1 level was lower, and vice versa. 
In conclusion, the tumors from the control group showed higher angiogeneic 
activity, which resulted in a faster tumor growth rate. However, whether such process 
is a direct effect of polysaccharopeptide or a secondary result due to changes in other 
systems，e.g. the immune system, remains to be investigated in the following chapter. 
4 4 
Plate 4.1 An overview of a tumor cast from the control group, showing a dense 
vascular network (25x). 
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Plate 4.2 Measurement of number ofblood vessels and area ofblood vessels. 
(a) Image captured by the Spot camera at a magnification of 100x. 
The blood vessels were stained brown. 
(b) The positively stained blood vessels were highlighted by hand 
drawing. 
(c) The areas enclosed by the outline were automatically filled by the 
software. “ 
(d) Region of fixed size was used to confme region for assessment. 
The number of blood vessels and their area were automatically 
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Plate 4.3 (a) Periphery of a tumor shows the transition of normal blood vessels 
to tumor vessels. The normal vessels were characterized by an even 
diameter, a straight course and a normal branching pattern (red 
arrows). Further to the left of the figure were the typical tumor 
vessels，with dilation and meandering courses (blue arrowheads) 
(220x). 
(b) The blood vessels at the periphery of a tumor form a vascular 







Plate 4.4 (a) The vasculature of muscles wrapped by the tumor tissues (lined by 
the red dotted lines) (30x). 
(b) The muscle fibres enclosed by the tumor tissues as shown under 
light microscope (blue arrows) (400x). 
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Plate 4.5 (a) Vasculature of dying muscles within tumor tissues. The blood 
vesssels were less regular and regression of muscular vasculature was 
seen (red arrows). This may result from nutrient deprivation due to the 
rapidly growing tumor (70x). 
(b) The muscle fibres wrapped by the tumor cells (blue arrow) had 




Plate 4.6 (a) Tumor vasculature was characterized by its highly varying density 
at the core of the tumor. The central portion of the vasculature had 
higher density and surrounded by comparatively avascular areas (30x). 
(b) Highly varying vascular density was demonstrated in light -
microscopic image, and a dense vascular region (enclosed by the red 







Plate 4.7 (a) Dense network of tumor sinusoids resulting from active 
angiogenesis can be seen at the core of the tumor. They served to 
nourish the rapidly growing tumor (30x). 
(b) Tumor sinusoids at higher magnification. They are usually 





Plate 4.8 (a) and (b) Glomeruloidal structure. These densely packed, coiled 
vessels were known as the ‘hot spots' of the tumor in immunostained 
sections. These regions also correspond to active angiogenesis 
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Plate 4.9 Plump protrusions. These are the budding areas where 
neovascularization was initiated (500x). 
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Plate 4.10 Overview of a tumor cast from the control group. The core of the 
tumor was composed of a dense network of tumor sinusoids (enclosed 
areas) (30x). 
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Plate 4.11 Overview of a tumor cast from the treated group. Many of the blood 
vessels seen are the muscle vasculature. Angiogenic features were 




Plate 4.12 Nodular structures in the treated group, representing more actively 
angiogenic areas (65x). 
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Plate 4.13 Periphery of a tumor from the treated group. 
(a) The periphery of the tumors from the treated group was surrounded 
by normal muscle vasculature or subcutaneous vasculature (30x). 






Plate 4.14 Leaky newly formed blood vessels. 
(a) Abundant extravasates can be seen in the control group, consisting 
of casting material leaking out from the newly formed blood 
vessels (190x). 
(b) Leaky vessels seen under light microscope (200x). The tumor 
tissue in the control group is infiltrated with red blood cells leaking 
out from the vasculature. The upper region shows intact 
endothelium (blue arrow) without spilling of red blood cells over 
the tumor tissue, indicating that the feature mentioned above is not 
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Chapter 5 Immunomodulation 
5.1 Introduction 
Since the immune response of the tumor-bearing hosts plays a very important role 
against tumor progression, the investigation of the immune response in experimental 
animal model and in clinical cases may provide clues for tumor therapy. In tumor-
bearing hosts, suppressed immunity is found to be related to depressed cell-mediated 
immunity (CMI) (Lee et al, 1994; Lucey et al, 1996). To eliminate the tumor cells, 
which are recognized as altered self-cells, both the T helper cells (Th) and T cytotoxic 
cells (Tc) are involved. Th cells can supply the activation and proliferation cytokine, 
interleukin-2 (DL-2) and other cytokines like interferon-y pFN-y) that is also secreted 
by Tc cells. In response to the activation signal, the Tc cells become active cytotoxic 
T lymphocytes (CTL) and are able to Iyse the target tumor cells. In tumor-bearing 
hosts, a decrease in Th cells (CD4+) is commonly found (Igarashi et al, 1992; Yuan et 
a/, 1992; Lee et al, 1994; Mitropoulos et al, 1995). This impairs the function ofthe 
“ 
lymphocytes against tumor growth by the reduction ofEL-2 and ffN-y production. 
Apart from cell-mediated immunity, the immune system can also elicit its anti-
tumor activity through inflammatory responses. Cytokines like the tumor necrosis 
factor-a (TNF-a) and interleukin-ip (n.-lp) can upregulate the expression of cell 
adhesion molecules (CAM) like ICAM-1, VCAM-1, E-seIectin, etc 0^annel et al, 
1993; Tamaru et al, 1998). Up-regulation of C A M promotes adhesion of 
lymphocytes, which in turn would mediate cytotoxic effect on tumor cells. Therefore, 
the immune responses are studied in two aspects: the lymphocyte proliferation and 
45 
activity, and the inflammatory response. Parameters for evaluation of immune 
response include lymphocyte population, proliferation and cytokine secretion. 
In the in vitro system, immune response of the lymphocytes can be studied 
through T cytotoxicity assay and proliferation assay (Frey, 1997). In this study, the 
proliferative effect of the polysaccharopeptide on the mouse splenocytes was 
investigated. 
With the advances of flow cytometry and development of monoclonal antibodies 
directed at specific lymphocyte surface antigens, especially the cluster of 
differentiation (CD), immunophenotyping facilitates advancement of the 
understanding the features of development, differentiation, and activation of 
lymphocyte subpopulations. 
In this study, 2-color fluorescence flow cytometry was used. The monoclonal 
antibodies were conjugated to fluorescein isothiocyanate (FITC) and phycoerythrin 
(PE), thus enabling the identification of four subpopulations in one cell population 
(Fleisher，1997). 
Table 5.1 Selected lymphocyte surface antigens (Fleisher et al, 1997) 
•I 
Cluster ofDifferentiation Location  
CD3 (T3, OKT3, Leu4) Found on T cells, multichain receptor associated with 
the T-cell antigen receptor.  
C D 4 (T4, OKT4, Leu3) Found on T-helper (Th) subset and low-density 
monocytes, cytoadhesion receptor for M H C class II 
binding, receptor for HIV.  
C D 8 (T8, OKT8, Leu2) Found on T-cytotoxic (Tc) subset and in low density on 
N K cells, cytoadhesion receptor for M H C class I 
binding.  
"55l9 (B4, QKB22, Leul2) Found on B cells and pre-B cells 
On the other hand, the cytokine gene expression pattern was also investigated 
using RT-PCR. The genes being studied include D^-2, JFN-y, TNF-a and E^-lp. The 
46 
changes of the weight of the spleens from both control and treated group were also 
compared. 
5.2 Materials and Methods 
5.2.1 Effect of the polysaccharopeptide on the proliferation of splenocytes 
The proliferation assay of murine splenocytes can be referred to Chapter 3， 
Section 3.2. 
5.2.2 Evaluation of spleen weight of tumor bearing mice 
BALB/c mice inoculated with S180 cells were maintained as stated in Section 2.2. 
Beginning from Day 9，4 mice were killed at 5-day intervals. The weight of the 
spleens were recorded and plotted against the days of tumor inoculation and tumor 
weight (Fig. 5.1 &Fig. 5.2). 
•I 
5.2.3 Lymphocyte subset analysis 
Materials ‘ 
Monoclonal antibodies included FITC-conjugated hamster anti-mouse 
CD3e, FITC-conjugated rat anti-mouse CD45, PE-conjugated rat anti-mouse CD4, 
C D 8 and CD19, isotype controls included FITC-conjugated hamster IgG, FITC-
conjugated IgG2b and PE-conjugated IgG2a. All antibodies were purchased from 
Pharmingen, U K except the CD45 from Coulter, USA. 
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Preparation of cells 
Beginning from Day 9，four mice from each group were killed by cervical 
dislocation and splenocytes from each mouse were isolated as described in Section 
5.2.1. The cells were resuspended at 2 x 10^/ml in PBS/FBS (PBS supplemented 
with 1% FBS). 
AJ1 staining processes were carried out in dark. The monoclonal antibodies were 
each diluted by PBS/TBS to a concentration of20^ig/ml. 50^ il ofthe diluted antibody 
was added. 1 x 10^ cells in 50^1, were incubated for 10 minutes at room temperature 
and thereafter made up to a final volume of 0.5ml with PBS/FBS. The samples were 
ready for analysis. Table 5.2 shows the combination ofantibodies used for two-color 
fluorescence. 
Table 5.2 Lymphocyte subpopuIations identified by two-color fluorescence 
staining. 
Antibody Combination Lymphocyte subpopulation targeted 
CD45+/CD4+ T helper cells  
CD45 /CD8+ T cytotoxic (or suppressor) cells 
CD3+/CD19+ |Tcells/Bcells — 
Flow cytometry 
Samples were analyzed on an EPICS® flow cytometer (Coulter Corporation, 
U S A ) configurated with 4 photomultiplier tubes and an air-cooled 488nm argon laser. 
FITC emission was reflected by a 550nm dichroic longpass filter and passed through 
a 525nm bandpass filter. PE emission was reflected by a dichroic longpass filter and 
passed through a 575nm bandpass filter. 
48 
Data acquisition and analysis 
Around ten thousand events for each sample were acquired in listmode format, 
with four-decade logarithmic amplification ofFITC and PE, and linear amplification 
of forward scatter and side scatter. Acquisition and analysis were performed with the 
Expo 2 software (Coulter Corporation, USA). 
5.2.4 Cytokine gene expression 
Spleens from tumor-bearing mice were taken out and divided into two portion, 
one portion for flow cytometric analysis and the other portion was frozen in liquid 
nitrogen and stored at -80°C for gene expression analysis. R N A extraction was 
performed for each sample as described in Section 4.2.3. Table 5.3 showed the 
information about the primers for the specific genes being amplified and the 
temperature, time, number of cycles and the size ofthe P C R product. 
The amplified products were separated and analyzed by the 1.2 % (w/v) agarose 
gel electrophoresis, and their intensities were quantified by the software ImageQuant 
and normalized with p-actin. 
5.2.5 Statistical Analysis 
The Mann-Whitney test was used to assess the significance in the difference in 
spleen weight between the control and the treated group. The difference was 
considered significant when the exact significance is greater than the asymptotic 
significance (E.S>A.S.). The Spearman ‘ s test was used to assess the correlation 































































































































































































































































































































































































































































































































































































































significant when p<0.001. The T independent samples test was used to assess the 
significance in the difference in lymphocyte subpopulations between the control 
group and the treated group. The difference between different days within the same 
group was similarly assessed. For the T independent samples test, the difference 
between the two groups was considered significant when p<0.001. All computations 
were done with SPSS Base 8.0 statistical software (USA).‘ 
5.3 Results 
5.3.1 Effect of the polysaccharopeptide on the proliferation of splenocytes 
The polysaccharopeptide exerted neither a mitogenic nor a cytotoxic effect on the 
murine splenocytes (Chapter 3，Fig. 3.3) at concentrations up to lmgAnl. There were 
slight variations in the percentage of proliferation but the difference is insignificant 
(p>0.001) 
4/ 
5.3.2 Evaluation of spleen weight of tumor bearing mice 
The weight of the spleens from the control group was found to be higher than that 
in the treated group (Fig. 5.1) by Mann-Whitney，s test. A positive correlation Was 
found between the spleen weight and the tumor weight by the Spearman's test 
(p<0.001) (Fig. 5.2)，indicating that the immune system was stimulated in tumor-
bearing mice, no matter with or without polysaccharopeptide treatment. 
50 
5.3.3 Lymphocyte subpopulation study 
The study of CD4+/CD8+ ratio indicated the relative abundance of T helper (Th) 
cells to T cytotoxic (Tc) cells while the CD3+/CD19+ ratio showed the ratio ofT cells 
to B cells. 
By statistical analysis, the CD4+/CD8+ ratio did not show significant difference 
(p>0.001) between the two groups and between Day 9 and Day 29 within the same 
group (Fig. 5.3 & Table 5.5). However, CD4+/CD8+ ratio of normal mice (2.615 士 
0.5872) is higher than that in the tumor-bearing mice. 
Table 5.4 CD4+/CD8+ ratio on different days of tumor inoculation. 
Control group Treated group 
O^ean 士 SEM) * (Mean 士 SEM) * 
DayO 2.615士0.5872  
Day9 1 . 8 7 1 5 土 0 . 3 2 9 3 1 . 9 4 3 3 士 0 . 1 7 1 2 
Day24 2.5658 ±0.0763 ~ 2.1370±0.0649 
^ y 2 9 1.8735 土0.0597 1.9935 土0.1389  
* S E M stands for standard error mean. 
Similarly, the difference in CD3+/CD19+ ratio was insignificant (p>0.001) 
between the control group and the treated group throughout the time course (Fig. 5.4 
& Table 5.5). The ratio on Day 9 and on Day 29 within the same group also showed 
no significant change. The ratio of the tumor-bearing mice in both groups also 
showed no deviation when compared to that of the normal mice ( 1 . 0 2 6 5 士 0 . 0 7 1 3 ) ： 
Table 5.5 CD3+/CD19+ ratio on different days of tumor inoculation. 
Control group Treated group 
(Mean 士 SEM) * (Mean 士 SEM) * 
1.0265 ±0.0713  
D a y 9 1.1252土0.2534 0.8517土0.0551 
Dayl9 1.1194士0.0899 ~ 0.9625 士0.1141 
Pay24 1.0115土0.0411 — 0.8630士0.0469 
Pay29 1.0279±0.1368 1.1452±0.1810 
* S E M stands for standard error mean. 
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5.3.4 Cytokine gene expression 
The results of RT-PCR that analysed the abundance of transcripts of cytokine 
genes in splenocytes are shown in Fig.5.5 (a)-(d). The level of JL-2, which is mainly 
responsible for the proliferation of T lymphocytes, dropped abruptly in both groups 
after Day 9. The levels ofD^-2 in both groups were similar fFigure 5.5 (a)). 
The level offfN-y was higher in the treated group at all time point except on Day 
19, when the levels were similar in both groups (Fig. 5.5 (b)). 
The levels ofTNF-a and JL-lf> were similar in both groups and the control group 
showed a slightly higher level of expression at the end of the experimental period 
(Fig.5.5(c)&(d)). 
5.4 Discussion 
In this study, analysis is mainly focused on changes in the spleen. Spleen is a 
large lymphoid organ in which anti-tumor immune response is delayed relative to,, 
immune response detected in draining lymph node (Frey, 1997). Two to six weeks 
after injection would be an appropriate time for analysis, which was used in this 
experiment. The advantages of using the spleen are (i) it provides a sufficient supply 
of immune cells for simultaneous analysis, like immunophenotyping and gene 
expression analysis, and (ii) It is also easier to locate compared to the draining lymph 
node in mice. 
Positive correlation was obtained between tumor weight and the weight of spleen, 
implying that the tumor burden did elicit an immune response in the mice. W e had 
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therefore in this study to investigate two aspects of immune response: lymphocyte 
proliferation, lymphocyte subset analysis and cytokine expression. 
The functional state of the immune system can be reflected in the relative 
abundance of different subsets of lymphocytes. Lymphocyte subpopulation analysis 
has been carried out extensively using tumor infiltrating lymphocytes (Igarashi et al, 
1992; Yuan et al, 1992), splenocytes (Yeung et al, 1992)，peripheral blood cells 
(Igarashi et al, 1992; Mitropoulos et al, 1995) and peritoneal fluid (Lacki et al, 1992; 
Borrione et al, 1996). 
In this study, the CD4+/CD8+ ratio was found to be suppressed when compared to 
that of the normal mice. The decrease was attributed to a decrease in the percentage 
of CD4+ cells while the percentage of CD8+ cells remained rather constant, as found 
in many other studies (Igarashi et al, 1992; Yuan et al, 1992; Lee et al, 1994; 
Mitropoulos et al, 1995), though some did not show any significant change 
(Mizoguchi et al, 1992). An increase in CD4+ cells may then serve to remedy the 
immune function. Osaki et al (1998) used interleukin-18 (EL-18) which mediated 
EFN-y and EL-12-independent antitumor effects. The CD4+/CD8+ ratio was increased 
“ 
and the results indicated that the antitumor effects were mediated by CD4+ T cells and 
N K cells. The treatment with the polysaccharopeptide in this study did not bring about 
any subsequent change in the ratio. This may imply that it did not mediate its action 
through clonal expansion of a lymphocyte subset. Such phenomenon was also fbund 
in other successful tumor therapies. Braczkowski et al (1998) discovered that TNF-a 
immunotherapy resulted in a decreased CD4+/CD8+ ratio in cancer patients together 
with an increase in N K cell activation in the in vitro system. 
The study ofCD3+/CD19+ ratio indicated the relative abundance ofT cells and B 
cells. The ratio did not change in relation to tumor progression (number of days of 
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tumor inoculation) or treatment. Many studies showed that B cells were not involved 
in immune response in tumor development except in B cell lymphoma (Holcombe et 
al, 1994; Muthukkumar et al, 1997; Nakata et al, 1997). The involvement ofB cells 
was mentioned in the immune enhancement theory in which the B cells produce IgM 
in response to the tumor antigen. However, the response is weak and can only 
detected at early development (Manson, 1994). 
Cytokines are plueritropic and redundant. The expression of cytokines 
investigated in this study can be separated briefly into two aspects. One aspect is their 
effect on the growth, differentiation and activation of lymphocytes. The other aspect 
is the induction of the inflammatory responses. 
In this study, it was found that the level of EL-2 dropped in both groups. Many 
investigations have shown that tumor progression result in decreased expression of 
EL-2 (Gallo et al, 1993; Ghosh et al, 1995; Lucey et al, 1996)，which is required to 
stimulate the growth and maintain the survival of proliferating T cells (Marrack et al, 
1998). This complied with our finding in flow cytometric analysis in that there was 
no significant proliferation of lymphocytes. Yet it was found that the 
“ 
polysaccharopeptide mediated its anti-tumor activity through up-regulation of 
lymphocyte activity. ffN-y can activate the Tc cells into mature CTL against the 
tumor cells. In the treated group, there was an up-regulation of EFN-y gene 
expression. ' 
TNF-a and H^-lp, the proinflammatory cytokines, together with ffN-y, mediate a 
series of events in inflammation. Expression of C A M s facilitates lymphocyte 
adhesion with consequent transmigration to the tumor tissue. Though the levels of 
gene expression TNF-a and IL-ip were slightly higher in the control group at the 
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later time point, this may not contribute to the anti-tumor activity because the 
activation and proliferation signal for lymphocytes, JL-2, had already diminished. 
As shown in Section 4.2.2, the expression of VEGF, angiogenic regulator, was 
lower in the treated group at the early stage and throughout the course. This implied a 
limited angiogenesis and thus growth in the tumors of the extract-treated group. It has 
been shown that ffT^-y has a role in suppressing the expression of V E G F (Dias et al, 
1998). The early up-regulation of ffN-y in the treated group may account for the 
down-regulation of VEGF expression. Meanwhile, the effect of mSl-y together with 
EL-2 at the early stage activated the Tc cells into cytotoxic T lymphocytes (CTL), 
which would carry out specific killing of the tumor cells. Expression of C A M in the 
presence of TNF-a and EL-ip promotes adhesion of lymphocytes, which in tum 
would mediate cytotoxic effect on tumor cells. 
As the tumor progression proceeded, there was decreasing expression of EL-2. 
This diminished the cytotoxic effect of CTLs towards the tumor, but a continuous 
supply of ffN-y allowed suppression of VEGF at a low level. Woessner et al (1997) 
has shown that tumor regression is related to a continuous decrease of V E G F m R N A 
expression while tumor growth inhibition is related to a stable expression of V E G F 
m R N A . The findings in this study complied with their result in that tumor growth 
inhibition rather than regression was observed, with a stable and low expression of 
V E G F m R N A . . 
From the results in cytokine gene expression and the lymphocyte subset analysis, 
it can be suggested that the polysaccharopeptide mediated the immunomodulation 
through an up-regulation of gene expression of EFN-y. This favored the cell-mediated 
anti-tumor activity. The down-regulation of VEGF expression in the treated group 
may also be attributed to the effect of ffN-y, but further experiments were required to 
55 
confirm this point. Taken all data together anti-angiogenesis and cell-mediated 
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Chapter 6 General Discussion 
Many polysaccharides from different sources have also shown anti-tumor activity 
(Wang et al, 1997; Ishihara et al, 1998). Most of the anti-tumor activity of these 
polysaccharides was found to be related to the up-regulation of the immune system 
(Wang et al, 1997; Ishihara et al, 1998; Habelha et al, 1998). Recent investigations 
have further demonstrated the anti-angiogenic anti-metastatic effects of these 
polysaccharides (Kanoh et al, 1994; Parish et al, 1987). In this study, 
polysaccharopeptide from Coriolus versicolor has been shown to possess anti-tumor 
activity against mice bearing S180 solid tumor. Many other investigations had been 
done on the anti-tumor activity of this polysaccharopeptide (Mori et al, 1987; Kanoh 
et al, 1994; Kobayashi et al, 1994，1995; Dong et al’ 1996)，while others on the 
immunoregulatory and angiogenic activities in the in vivo model. Anti-tumor activity 
of a compound can be mediated in different pathways or a combination of them. It 
can be conducted by cytotoxicity of the compound on the tumor cells, as most of the 
current chemotherapeutic drugs are of this type. Tumor growth can also be inhibited 
through inhibition on angiogenesis, whereby tumor growth is checked by the lack of 
nutrients and oxygen supply. Up-regulation of the immune system augments the 
immune cell functions and cytokine or antibody secretion against the tumor cells. In 
this study, all three aspects were investigated in the S180 tumor bearing mice to get a 
more comprehensive picture on the effect of this polysaccharopeptide on tumor 
growth. The in vitro cell assay showed that the anti-proliferative effect of the 
polysaccharopeptide against S180 cells was achieved at a concentration above 
200^g/ml. Though this concentration was much higher than the one given as oral 
treatment in drinking water, there was not enough or direct evidences on whether it 
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kills the tumor cells through metabolic activation or accumulation of toxic metabolites 
in the tumor cells. 
Our results from the microcorrosion casting in Chapter 4 showed more active 
angiogenesis in the tumor casts from the control group which possessed more tortuous 
blood vessels, leaky vessels, tumor sinusoids and capillary sprouts. On the other 
hand, angiogenic features were only seen at scattered portions of the cast, implying 
more limited angiogenesis in the treated group. 
The vascular density in terms of number of blood vessels per unit area of tumor 
was highly correlated with the tumor weight (Fig. 4.1). Assessment of vascular 
density has been proven to be of high prognostic values in clinical cases, suggesting 
that angiogenesis was highly related to tumor growth. A lower vascular density and 
lower tumor weight in the treated group indicated that the polysaccharopeptide 
inhibited tumor growth through anti-angiogenic pathway. 
The study of angiogenic gene expression further provided information on the 
effect ofthe polysaccharopeptide at a molecular level. Results in Chapter 4 showed a 
marked decrease of VEGF expression in the treated group. VEGF is very crucial in “ 
the process of angiogenesis, since it is the direct and the only angiogenic factor that 
specifically stimulates the endothelial cell proliferation. The V E G F receptors, 
especially the flk-l, were under the regulation of VEGF. It decreased with uprising 
level ofVEGF and vice versa. Expression of flt-1 was, however, not much affected. 
The third aspect studied is the immune response of the mice to the treatment. The 
immune response was evaluated in two aspects: the relative proportion of immune 
cells and the cellular cytokine expression. 
Many researches have shown a depressed CD4+/CD8+ ratio in tumor-bearing 
hosts. In this study, tumor-bearing mice in both groups did show a lowered ratio 
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(Table 5.4). However, the ratio neither changes prominently along tumor progression 
nor changes after treatment, and similarly for CD3+/CD19+ ratio. Our results show 
that the formation of tumor has little to no effect on the ratios, and the treatment did 
not produce any effect on the relative abundance ofT cells and B cells, either. Since 
an absolute count of lymphocytes was not done, the possibility of proliferation in both 
T cells and B cells induced by EL-2, especially in the earlier period of the study, 
cannot be excluded. 
The analysis of cytokine transcription demonstrated a prominent effect in the 
expression of ffW-y. The effect of DFN-y is two-fold. It is known as a type 1 
cytokine, which can suppress the expression of type 2 cytokines like IL-6 and EL-4. It 
has been shown that a dominance in type 1 cytokines is favorable for cell-mediated 
immunity, a process very important to killing of tumor cells. EFN-y specifically 
activates the Tc into CTL. It can also activate the macrophages to secrete 
inflammatory cytokines like TNF-a, which can also facilitate the killing of tumor 
cells. 
” 
The action of different systems, instead of independent, is rather interactive. EFN-
Y not only has an effect on the immune system, but it also down-regulates the 
expression of VEGF. It was shown that a stable level of V E G F produced an 
inhibitory effect on tumor growth, but not regression. The results obtained in this 
study agreed with this argument (Fig. 2.2). 
The use of an animal model in studying the anti-tumor effect of a treatment can 
give a more complete picture on the interaction of different factors or systems in 
mediation of its effect. This mimics more closely to tumor growth and inhibition in 
humans, but it also poses some limitations on the interpretation of the experimental 
results. The use of an animal model requires a large sample size to generate 
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reproducible results. In vivo study involves more complicated interaction within the 
body, some of which may be out of scope of our study. Though the use of inbred 
mice eliminates some of the differences caused by genetic differences, each individual 
still possesses different responses to the tumor and to the treatment. Owing to some 
practical limitations in the study like the time and supply of mice, only a few trials 
can be done. 
In conclusion, the polysaccharopeptide was shown to mediate anti-tumor activity 
through anti-angiogenesis and up-regulation of the immune system. For the study on 
angiogenesis, other than VEGF, factors like angiopoietins and their receptors, Tffi-2 
can be studied. They do not stimulate endothelial cell proliferation but are crucial to 
the structure of the blood vessels. Immunostaining of the tumor sections with 
antibody against V E G F can show the differential expression of V E G F in different 
parts of a tumor (Barton et al, 1997; Maeda et al, 1998), which can give more 
information on interaction of different cell types on the effect of V E G F expression. 
Flow cytometry using intracellular staining of EL-2 and EFN-y can be used to 
investigate the cell type responsible for the cytokine secretion (Mascher et al, 1999).“ 
Moreover, peripheral blood or draining lymph node can be used for analysis of 
immune response. They are in direct contact with the tumor and thus can give more 
accurate information on interaction of the tumor with the immune system. 
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